Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RPID 
Rapid Micro Biosystems Inc (RPID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: RPID (3-star) is a REGULAR-BUY. BUY since 13 days. Simulated Profits (-3.64%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 105.45% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 129.98M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 3 | Beta 1.39 | 52 Weeks Range 0.83 - 4.50 | Updated Date 10/17/2025 |
52 Weeks Range 0.83 - 4.50 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -145.63% | Operating Margin (TTM) -167.28% |
Management Effectiveness
Return on Assets (TTM) -29.89% | Return on Equity (TTM) -59.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 130386457 | Price to Sales(TTM) 4.29 |
Enterprise Value 130386457 | Price to Sales(TTM) 4.29 | ||
Enterprise Value to Revenue 4.3 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 39710799 | Shares Floating 19338040 |
Shares Outstanding 39710799 | Shares Floating 19338040 | ||
Percent Insiders 9.6 | Percent Institutions 59.55 |
Upturn AI SWOT
Rapid Micro Biosystems Inc
Company Overview
History and Background
Rapid Micro Biosystems, Inc. was founded in 2006 and focuses on providing automated, non-destructive rapid microbial detection, enumeration, and identification for the pharmaceutical, biotechnology, and personal care industries. It went public in December 2021. The company's growth has been driven by the increasing need for faster and more accurate microbial testing in these industries.
Core Business Areas
- Growth Direct System: Automated system for rapid microbial detection and enumeration. This is the core product offering.
- Consumables: Consumable products required for use with the Growth Direct system, providing recurring revenue.
- Services: Service and support related to the Growth Direct system, including installation, training, and maintenance.
Leadership and Structure
The leadership team includes key executives in areas such as CEO, CFO, and heads of research and development, sales, and marketing. The organizational structure is typically functional, with departments focused on product development, manufacturing, sales, marketing, and customer support.
Top Products and Market Share
Key Offerings
- Growth Direct System: The Growth Direct System automates and accelerates microbial testing, significantly reducing testing time compared to traditional methods. Competitors include traditional plate counting methods and alternative rapid microbial methods from companies like bioMu00e9rieux and Charles River Laboratories. Market share data is difficult to determine precisely without access to proprietary data, but Rapid Micro Biosystems aims to capture a significant portion of the rapid microbial testing market, estimated to be worth hundreds of millions of dollars annually. Revenue derived from this product is the vast majority of the company's total revenue.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industries are heavily regulated and require extensive microbial testing throughout the manufacturing process. The trend is toward faster, more accurate, and automated testing methods to improve efficiency and reduce risks.
Positioning
Rapid Micro Biosystems is positioned as a provider of innovative, automated microbial testing solutions. Its competitive advantages include faster time to results, reduced labor costs, and improved data integrity compared to traditional methods.
Total Addressable Market (TAM)
The TAM for rapid microbial detection is estimated to be over $1 billion. Rapid Micro Biosystems is positioned to capture a significant share of this market through its automated platform and focus on key industry verticals.
Upturn SWOT Analysis
Strengths
- Automated technology
- Faster time to results
- Improved data integrity
- Strong focus on pharmaceutical and biotech industries
Weaknesses
- High upfront cost of Growth Direct system
- Reliance on a single product line
- Limited market awareness compared to larger competitors
- Negative profitability
Opportunities
- Expansion into new geographic markets
- Development of new applications for Growth Direct system
- Partnerships with pharmaceutical and biotech companies
- Increased adoption of automation in microbial testing
Threats
- Competition from established players like bioMu00e9rieux and Charles River Laboratories
- Technological advancements that could render Growth Direct system obsolete
- Economic downturn that could reduce capital spending by pharmaceutical and biotech companies
- Regulatory changes that could impact microbial testing requirements
Competitors and Market Share
Key Competitors
- BIO
- CRL
- PCTI
Competitive Landscape
Rapid Micro Biosystems competes with established players like bioMu00e9rieux and Charles River Laboratories, as well as smaller companies offering alternative rapid microbial testing solutions. The company's competitive advantages include its automated technology and faster time to results. Disadvantages include its smaller size and limited market awareness compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increasing adoption of the Growth Direct system in the pharmaceutical and biotechnology industries. Revenue growth is positive, but profitability remains a challenge.
Future Projections: Future growth is projected to be driven by continued adoption of the Growth Direct system, expansion into new markets, and development of new applications. Analyst estimates depend on the specific firm and macroeconomic conditions.
Recent Initiatives: Recent strategic initiatives may include new product development, partnerships, and market expansion efforts.
Summary
Rapid Micro Biosystems is a relatively young company with innovative automated microbial testing technology that addresses a critical need in the pharmaceutical and biotech industries. While its growth trajectory is promising, profitability remains a challenge. The company faces competition from larger, more established players and must continue to innovate and expand its market presence to achieve its full potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise. Financial data should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapid Micro Biosystems Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 163 | Website https://www.rapidmicrobio.com |
Full time employees 163 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.